ophthalmologyОфтальмологияOphthalmology in Russia1816-50952500-0845Ophthalmology10.18008/1816-5095-2019-4-501-507ophthalmology-1084Research ArticleКЛИНИЧЕСКИЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯCLINICAL & EXPERIMENTAL RESEARCHЗначение скрининговых опросников для выявления риска развития возрастной макулярной дегенерацииThe Significance of Screening Questionnaire in the Evaluation of Age-Related Macular Risk Degeneration Developmenthttps://orcid.org/0000-0001-5784-3402КочмашеваЛ. А.KochmashevaL. A.

заведующая офтальмологическим отделением консультативно‑диагностической поликлиники

ул. Волгоградская, 185, Екатеринбург, 620016, Российская Федерация

head of the department of counselling diagnostic clinic

Volgogradskaya str., 185, Yekaterinburg, 620016, Russian Federation

lakochmasheva@mail.ruhttps://orcid.org/0000-0002-7667-5149ПрохороваЗ. Ю.ProkhorovaZ. Yu.

врач‑офтальмолог консультативно‑диагностической поликлиники

ул. Волгоградская, 185, Екатеринбург, 620016, Российская Федерация

Ophthalmologist

Volgogradskaya str., 185, Yekaterinburg, 620016, Russian Federation

https://orcid.org/0000-0003-1968-5655ГриневА. Г.GrinevA. G.

доктор медицинских наук, заведующий офтальмологическим отделением

ул. Волгоградская, 185, Екатеринбург, 620016, Российская Федерация

МD, head of the department of ophthalmology

Volgogradskaya str., 185, Yekaterinburg, 620016, Russian Federation

ГБУЗ СО «Свердловская областная клиническая больница № 1»РоссияSverdlovsk Regional Clinical Hospital № 1Russian Federation201926122019164501507Copyright © Кочмашева Л.А., Прохорова З.Ю., Гринев А.Г., 20192019Кочмашева Л.А., Прохорова З.Ю., Гринев А.Г.Kochmasheva L.A., Prokhorova Z.Y., Grinev A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ophthalmojournal.com/opht/article/view/1084Цель

Цель: оценить диагностическую значимость и объективизацию результатов скринингового опросника STARS для определения риска развития возрастной макулярной дегенерации (ВМД).

Пациенты и методы

Пациенты и методы. В исследование были включены 124 пациента (206 глаз): 40 мужчин (32,3 %), 84 женщины (67,7 %), самостоятельно заполнивших скрининговый опросник. Все пациенты были направлены на консультацию без подозрения и когда-либо установленного диагноза ВМД и любого другого заболевания сетчатки. С целью объективизации количества баллов и структурных изменений сетчатки дополнительно проведена оптическая когерентная томография сетчатки (ОКТ) и определение оптической плотности макулярного пигмента (ОПМП).

Результаты

Результаты. Значимо различалось не только количество баллов у пациентов без ВМД и с впервые установленным диагнозом ВМД, но и некоторые структурные показатели: средняя толщина сетчатки и объем сетчатки в области фовеа по данным ОКТ с достоверностью р < 0,05. Выявлен положительный тренд, указывающий, что с ростом числа баллов увеличивается предполагаемая стадия ВМД по AREDS. Установлена положительная связь количества баллов с риском развития ВМД, впервые выявленным диагнозом ВМД, с максимальной ОПМП, со средней ОПМП и центральной толщиной сетчатки (ЦТС). Площадь под ROC-кривой составила 0,62.

Заключение

Заключение. Опросник STARS — новый простой самозаполняемый опросник, достоверно разграничивающий группы риска развития и прогрессирования ВМД и может быть рекомендован для использования в ежедневной практике.

Aim

Aim: to evaluate the diagnostic value and objectification of the STARS questionnaire in the evaluation of risk of age-related macular degeneration (AMD) development.

Patients and methods

Patients and methods. 104 patients (206 eyes) 40 males (32.3 %), 84 women (67.7 %), who filled the self-administered STARS screening questionnaire, were enrolled in the study. All patients were referred without suspicion or established diagnosis of AMD of any other retinal pathology. Optical coherent tomography (OCT) and macular pigment optical density (MPOD) were carried out in order to objectify questionnaire score points and retinal structural changes.

Results

Results. The significant difference was found between patient without AMD and those with newly established AMD diagnosis not only in questionnaire score but also in some structural changes indicators: mean retinal thickness, foveal retinal thickness by OCT (<0.05). The direct correlation between increase in questionnaire points and estimate AMD stage by AREDS was found as well as the direct correlation between questionnaire score points and risk of AMD development, newly established AMD diagnosis, maximal macular pigment optical density (MPOD), mean macular pigment optical density and central retinal  thickness. The area under ROC-curve was 0.62.

Conclusion

Conclusion. STARS is a new, simple, self-administered questionnaire which accurately distinguishes AMD development and progression risk groups and can be recommended for routine use in every day practice.

возрастная макулярная дегенерацияскринингопросникрискage-related macular degenerationscreeningquestionnaireriskReferencesВласова И.А., Агапитов А.Е., Губин Г.И., Губин Д.Г. Профилактическая медицина: предмет и содержание (лекция 2). Сибирский медицинский журнал. 2005;55(6):94–96.Vlasova I.A., Agapitov A.E., Gubin G.I., Gubin D.G. Preventive medicine: subject and content (lecture 2). Siberian Medical Journal = Sibirskij medicinskij zhurnal. 2005;55(6):94–96 (In Russ.)Wilson J.M.G., Jungner G. Principles and practice of screening for disease. WHO Chronicle Geneva: World Health Organization. 1968.22(11):473. Public Health Papers, #34.Wilson J.M.G., Jungner G. Principles and practice of screening for disease. WHO Chronicle Geneva: World Health Organization. 1968.22(11):473. Public Health Papers, #34.Congdon N., et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–485. DOI: 10.1001/ar‑chopht.122.4.477Congdon N., et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–485. DOI: 10.1001/ar‑chopht.122.4.477Colijn J.M. Prevalence of Age‑Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017;124:1753–1763. DOI: 10.1016/j.ophtha.2017.05.035Colijn J.M. Prevalence of Age‑Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017;124:1753–1763. DOI: 10.1016/j.ophtha.2017.05.035Федеральные Клинические Рекомендации. Ассоциация врачей‑офтальмологов 2013. https://eyepress.ru/periodical.aspx?11 [Federal Clinical Recommendations. Association of Ophthalmologists (In Russ.)]https://eyepress.ru/periodical.aspx?11 Federal Clinical Recommendations. Association of Ophthalmologists (In Russ.)Нероев В.В. Российское наблюдательное эпидемиологическое неинтервенционное исследование пациентов с влажной формой возрастной макулярной дегенерации. Российский офтальмологический журнал. 2011;4(2): 4–9.Neroev V.V. Russian observational epidemiological non‑interventional study of patients with a wet form of age‑related macular degeneration. Russian ophthalmological journal = Rossiyskiy oftal’mologicheskiy zhurnal. 2011;4(2):4–9 (In Russ.)Evans J.R., Fletcher A.E., Wormald R.P.L. Causes of visual impairment in people aged 75 years and older in Britain: an add on study to the MRC Trial of Assessment and management of older people in the community. Br J Ophthalmol. 2004;88:365–370. DOI: 10.1136/bjo.2003.019927Evans J.R., Fletcher A.E., Wormald R.P.L. Causes of visual impairment in people aged 75 years and older in Britain: an add on study to the MRC Trial of Assessment and management of older people in the community. Br J Ophthalmol. 2004;88:365–370. DOI: 10.1136/bjo.2003.019927Friedman D.S., O’Colmain B.J., Munoz B., et al. Prevalence of age‑related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–572. DOI: 10.1001/archopht.122.4.564Friedman D.S., O’Colmain B.J., Munoz B., et al. Prevalence of age‑related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564–572. DOI: 10.1001/archopht.122.4.564Lim L.S., Mitchell P., Seddon J.M. Age‑related macular degeneration. Lancet. 2012;379:1728–1738. DOI: 10.1016/S0140‑6736(12)60282‑7Lim L.S., Mitchell P., Seddon J.M. Age‑related macular degeneration. Lancet. 2012;379:1728–1738. DOI: 10.1016/S0140‑6736(12)60282‑7Brown G.C., Brown M.M., Sharma S. Difference between ophthalmologists’ and patients’ perceptions of quality of life associated with age–related macular degeneration. Can. J. Ophthalmol. 2000;35(3):127–133.Brown G.C., Brown M.M., Sharma S. Difference between ophthalmologists’ and patients’ perceptions of quality of life associated with age–related macular degeneration. Can. J. Ophthalmol. 2000;35(3):127–133.Hart P.M., Chakravarthy U., Stevenson M.R. Questionnaire based survey on the importance of quality of life measures in ophthalmic practice. Eye. 1998;12(Pt 1):124–126. DOI: 10.1038/eye.1998.20Hart P.M., Chakravarthy U., Stevenson M.R. Questionnaire based survey on the importance of quality of life measures in ophthalmic practice. Eye. 1998;12(Pt 1):124–126. DOI: 10.1038/eye.1998.20Linder M., Chang T.S., Scott I.U., Hay D., Chambers K., Sibley L.M., et al. Validity of the visual function index (VF–14) in patients with retinal disease. Arch. Ophthalmol. 1999;117(12):1611–1616. DOI: 10.1001/archopht.117.12.1611Linder M., Chang T.S., Scott I.U., Hay D., Chambers K., Sibley L.M., et al. Validity of the visual function index (VF–14) in patients with retinal disease. Arch. Ophthalmol. 1999;117(12):1611–1616. DOI: 10.1001/archopht.117.12.1611McClure M.E., Hart P.M., Jackson A.J., Stevenson M.R., Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability. Br. J. Ophthalmol. 2000;84:244–250. DOI: 10.1136/bjo.84.3.244McClure M.E., Hart P.M., Jackson A.J., Stevenson M.R., Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability. Br. J. Ophthalmol. 2000;84:244–250. DOI: 10.1136/bjo.84.3.244Mills R.P. Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis. Trans. Am. Ophthalmol. Soc. 1998;96:753.Mills R.P. Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis. Trans. Am. Ophthalmol. Soc. 1998;96:753.Yelin E. Measuring Functional Capacity of Persons with Disabilities in Light of Emerging Demands in the Workplace. NAP. 1999. Available from:Yelin E. Measuring Functional Capacity of Persons with Disabilities in Light of Emerging Demands in the Workplace. NAP. 1999. Available from:https://www.ncbi.nlm.nih.gov/books/NBK230769/https://www.ncbi.nlm.nih.gov/books/NBK230769/Brown G.C., Brown M.M., Sharma S. Difference between ophthalmologists’ and patients’ perceptions of quality of life associated with age–related macular degeneration. Can. J. Ophthalmol. 2000;35(3):127–133.Brown G.C., Brown M.M., Sharma S. Difference between ophthalmologists’ and patients’ perceptions of quality of life associated with age–related macular degeneration. Can. J. Ophthalmol. 2000;35(3):127–133.Hazel C.A., Petre K.L., Armstrong R.A., Benson M.T., Frost N.A. Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest.Ophthalmol. Vis. Sci. 2000;41(6):1309–1315.Hazel C.A., Petre K.L., Armstrong R.A., Benson M.T., Frost N.A. Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest.Ophthalmol. Vis. Sci. 2000;41(6):1309–1315.Resnikoff S., Pascolini D., Etya’ale D. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–851. DOI: S0042‑96862004001100009Resnikoff S., Pascolini D., Etya’ale D. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–851. DOI: S0042‑96862004001100009Wang F., Tielsch J.M., Ford D.E., Quigley H.A., Whelton P.K. Evaluation of screening schemes for eye disease in a primary care setting. Ophthalmic Epidemiol. 1998 Jun;5(2):69–82. DOI: 10.1076/opep.5.2.69.1575Wang F., Tielsch J.M., Ford D.E., Quigley H.A., Whelton P.K. Evaluation of screening schemes for eye disease in a primary care setting. Ophthalmic Epidemiol. 1998 Jun;5(2):69–82. DOI: 10.1076/opep.5.2.69.1575Heesterbeek T.J., de Jong E.K., Acar I.E., Groenewoud J.M.M., Liefers B., Sánchez C.I., Peto T., Hoyng C.B., Pauleikhof D., Hense H.W., den Hollander A.I. Genetic risk score has added value over initial clinical grading stage in predicting disease progression in age‑related macular degeneration. Sci Rep. 2019;9:6611. DOI: 10.1038/s41598‑019‑43144‑3Heesterbeek T.J., de Jong E.K., Acar I.E., Groenewoud J.M.M., Liefers B., Sánchez C.I., Peto T., Hoyng C.B., Pauleikhof D., Hense H.W., den Hollander A.I. Genetic risk score has added value over initial clinical grading stage in predicting disease progression in age‑related macular degeneration. Sci Rep. 2019;9:6611. DOI: 10.1038/s41598‑019‑43144‑3Seddon J.M., Reynolds R., Yu Y., Daly M.J., Rosner B. Risk models for progression to advanced age‑related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology. 2011;118:2203–2211. DOI: 10.1016/j.ophtha.2011.04.029Seddon J.M., Reynolds R., Yu Y., Daly M.J., Rosner B. Risk models for progression to advanced age‑related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology. 2011;118:2203–2211. DOI: 10.1016/j.ophtha.2011.04.029Buitendijk G.H., Rochtchina E., Myers C. Prediction of age‑related macular degeneration in the general population: the Three Continent AMD Consortium. Ophthalmology. 2013; 120: 2644–2655. DOI: 10.1016/j.ophtha.2013.07.053Buitendijk G.H., Rochtchina E., Myers C. Prediction of age‑related macular degeneration in the general population: the Three Continent AMD Consortium. Ophthalmology. 2013; 120: 2644–2655. DOI: 10.1016/j.ophtha.2013.07.053Seddon J.M., Reynolds R., Yu Y., Rosner B. Validation of a prediction algorithm for progression to advanced macular degeneration subtypes. JAMA Ophthalmol. 2013;131:448–455. DOI: 10.1001/jamaophthalmol.2013.2578Seddon J.M., Reynolds R., Yu Y., Rosner B. Validation of a prediction algorithm for progression to advanced macular degeneration subtypes. JAMA Ophthalmol. 2013;131:448–455. DOI: 10.1001/jamaophthalmol.2013.2578Chiu C.J., Mitchell P., Klein R. A risk score for the prediction of advanced agerelated macular degeneration: development and validation in 2 prospective cohorts. Ophthalmology. 2014;121:1421–1427. DOI: 10.1016/j.ophtha.2014.01.016Chiu C.J., Mitchell P., Klein R. A risk score for the prediction of advanced agerelated macular degeneration: development and validation in 2 prospective cohorts. Ophthalmology. 2014;121:1421–1427. DOI: 10.1016/j.ophtha.2014.01.016Yu Y. Prospective Assessment of Genetic Effects on Progression to Different Stages of Age‑Related Macular Degeneration Using Multistate Markov Models; IOVS. 2012;53(3):1548–1556 DOI: 10.1167/iovs.11‑8657Yu Y. Prospective Assessment of Genetic Effects on Progression to Different Stages of Age‑Related Macular Degeneration Using Multistate Markov Models; IOVS. 2012;53(3):1548–1556 DOI: 10.1167/iovs.11‑8657Seddon J.M. et al. Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes. JAMA Ophthalmol. 2013;131(4):448–455 DOI: 10.1001/jamaophthalmol.2013.2578Seddon J.M. et al. Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes. JAMA Ophthalmol. 2013;131(4):448–455 DOI: 10.1001/jamaophthalmol.2013.2578Seddon J.M. The US twin study of age‑related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 2005; 23(3): 321–327. DOI: 10.1001/archopht.123.3.321Seddon J.M. The US twin study of age‑related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 2005; 23(3): 321–327. DOI: 10.1001/archopht.123.3.321Seddon J.M., Silver R.E., Kwong M., Rosner B. Risk prediction for progression of macular degeneration: 10 common and rare genetic variants, demographic, environmental, and macular covariates. Invest Ophthalmol Vis Sci. 2015;56:2192–2202. DOI: 10.1167/iovs.14‑15841Seddon J.M., Silver R.E., Kwong M., Rosner B. Risk prediction for progression of macular degeneration: 10 common and rare genetic variants, demographic, environmental, and macular covariates. Invest Ophthalmol Vis Sci. 2015;56:2192–2202. DOI: 10.1167/iovs.14‑15841Кулик А. В., Богомолов А. В. Метод прогнозирования риска развития макулодистрофии. Медицинский Вестник Северного Кавказа.2016;11(3):448–445. DOI: 10.14300/mnnc.2016.11101Kulik A.V., Bogomolov A.V. Method for predicting the risk of macular degeneration. Medical News of North Caucasus = Medicinskij vestnik Severnogo Kavkaza. 2016;11(3):448–445 (In Russ.). DOI: 10.14300/mnnc.2016.11101Delcourt C., Souied E., Sanchez A., Bandello F.; STARS Survey Group. Development and Validation of a Risk Score for Age‑Related Macular Degeneration: The STARS Questionnaire. Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6399–6407. DOI: 10.1167/iovs.17‑21819Delcourt C., Souied E., Sanchez A., Bandello F.; STARS Survey Group. Development and Validation of a Risk Score for Age‑Related Macular Degeneration: The STARS Questionnaire. Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6399–6407. DOI: 10.1167/iovs.17‑21819

The authors declare that there are no conflicts of interest present.